Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $2.6B | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B | $2.5B | $2.3B | $2.3B | $2.2B | $2.1B | $2.0B | $2.2B | $2.1B | $2.1B | $2.1B | $1.9B | $1.8B | $1.8B | $1.5B | $1.3B |
| Beneficio bruto | $1.3B | $1.3B | $1.4B | $1.4B | $1.6B | $1.6B | $1.4B | $1.3B | $1.2B | $1.2B | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B | $1.2B | $1.1B | $1.0B | $963M | $791M | $713M |
| % de margen bruto | 51.9% | 52.0% | 53.7% | 53.4% | 55.9% | 56.0% | 56.5% | 54.4% | 53.5% | 55.0% | 55.0% | 55.5% | 54.2% | 55.3% | 56.1% | 56.8% | 56.6% | 56.0% | 54.5% | 54.2% | 55.9% |
| Ingresos operativos (EBIT) | $235M | $270M | $269M | $338M | $483M | $500M | $421M | $230M | ($109M) | $117M | $53M | $167M | $150M | $169M | $264M | $295M | $284M | $231M | $183M | $135M | $146M |
| % de margen operativo | 9.1% | 10.5% | 10.5% | 12.7% | 17.2% | 17.1% | 16.6% | 9.9% | -4.7% | 5.4% | 2.6% | 8.3% | 6.9% | 8.0% | 12.8% | 14.2% | 14.7% | 13.0% | 10.4% | 9.2% | 11.5% |
| Ingresos netos | $222M | $760M | ($1.8B) | ($637M) | ($3.6B) | $4.3B | $3.8B | $1.8B | $361M | $115M | $28M | $113M | $89M | $78M | $169M | $178M | $185M | $145M | $90M | $93M | $103M |
| % de margen neto | 8.6% | 29.4% | -71.9% | -23.9% | -129.4% | 145.6% | 149.8% | 76.1% | 15.8% | 5.3% | 1.4% | 5.6% | 4.1% | 3.6% | 8.2% | 8.6% | 9.6% | 8.1% | 5.1% | 6.4% | 8.1% |
| EBITDA | — | $1.2B | ($2.1B) | ($655M) | ($4.5B) | $5.6B | $5.1B | $2.5B | $675M | $270M | $206M | $299M | $304M | $305M | $404M | $410M | $393M | $335M | $272M | $220M | $229M |
| Beneficio por acción (EPS) | $8.25 | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.47 | $58.27 | $11.94 | $3.82 | $0.95 | $3.85 | $3.05 | $2.69 | $5.91 | $6.26 | $6.59 | $5.20 | $3.24 | $3.41 | $3.83 |
| Acciones en circulación (M) | — | 27M | 28M | 29M | 30M | 30M | 30M | 30M | 30M | 30M | 30M | 29M | 29M | 29M | 29M | 28M | 28M | 28M | 28M | 27M | 27M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de BIO. /companies/us/BIO
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms